4.96
-0.03 (-0.50%)
| Previous Close | 4.98 |
| Open | 5.05 |
| Volume | 162,349 |
| Avg. Volume (3M) | 234,534 |
| Market Cap | 183,803,248 |
| Price / Sales | 66.02 |
| Price / Book | 56.83 |
| 52 Weeks Range | |
| Earnings Date | 10 Jun 2025 - 25 Jun 2025 |
| Operating Margin (TTM) | -4,013.86% |
| Diluted EPS (TTM) | -1.98 |
| Quarterly Revenue Growth (YOY) | -1.50% |
| Total Debt/Equity (MRQ) | 2.23% |
| Current Ratio (MRQ) | 4.51 |
| Operating Cash Flow (TTM) | -61.24 M |
| Levered Free Cash Flow (TTM) | -43.65 M |
| Return on Assets (TTM) | -88.08% |
| Return on Equity (TTM) | -186.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bearish | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Mixed | |
| Stock | Anteris Technologies Global Cor | - | - |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.25 |
|
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 4.04% |
| % Held by Institutions | 49.10% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| L1 Capital Pty Ltd | 31 Dec 2024 | 2,788,683 |
| Sio Capital Management, Llc | 31 Dec 2024 | 2,370,000 |
| Regal Partners Ltd | 31 Dec 2024 | 1,293,861 |
| One68 Global Capital, Llc | 31 Dec 2024 | 288,914 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 31 Mar 2025 | Announcement | Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV |
| 21 Mar 2025 | Announcement | Anteris Reports One-Year Patient Outcomes for DurAVR® THV |
| 12 Mar 2025 | Announcement | Anteris Reports 2024 Financial Results and Provides Corporate Update |
| 28 Feb 2025 | Announcement | Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |